EYEGATE PHARMACEUTICALS, INC. (NASDAQ:EYEG) Files An 8-K Regulation FD Disclosure
Item 7.01.
| Regulation FD Disclosure. |
EyeGate Pharmaceuticals, Inc. (the Company) hereby furnishes the
updated investor presentation attached as Exhibit 99.1 to this
Current Report on Form 8-K, which the Company may use in
presentations to investors from time to time, including at the
35th Annual J.P. Morgan Healthcare Conference, being
held January 9-13, 2017, in San Francisco, CA.
The information furnished to Item 7.01, including Exhibit 99.1,
shall not be deemed filed for the purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act)
and will not be deemed to be incorporated by reference into any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except to the extent that the Company specifically
incorporates it by reference.
The information furnished in this report, including Exhibit 99.1,
shall not be deemed to constitute an admission that such
information or exhibit is required to be furnished to Regulation
FD or that such information or exhibit contains material
information that is not otherwise publicly available. In
addition, the Company does not assume any obligation to update
such information or exhibit in the future.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
The Company hereby files the following exhibit:
| 99.1 | Presentation of the Company, dated as of January 9, 2017. |
About EYEGATE PHARMACEUTICALS, INC. (NASDAQ:EYEG)
Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye. EYEGATE PHARMACEUTICALS, INC. (NASDAQ:EYEG) Recent Trading Information
EYEGATE PHARMACEUTICALS, INC. (NASDAQ:EYEG) closed its last trading session up +0.06 at 1.66 with 49,932 shares trading hands.
